1. Fiorella D, Lylyk P, Szikora I, Kelly ME, Albuquerque FC, McDougall CG, et al. Curative cerebrovascular reconstruction with the Pipeline embolization device: the emergence of definitive endovascular therapy for intracranial aneurysms. J Neurointerv Surg 2018;10(Suppl 1):i9-i18.
2. Daou B, Starke RM, Chalouhi N, Barros G, Tjoumakaris S, Rosenwasser RH, et al. P2Y12 reaction units: effect on hemorrhagic and thromboembolic complications in patients with cerebral aneurysms treated with the pipeline embolization device. Neurosurgery 2016;78:27-33.
3. Daou B, Starke RM, Chalouhi N, Barros G, Tjoumakaris S, Rosenwasser RH, et al. P2Y12 reaction units: effect on hemorrhagic and thromboembolic complications in patients with cerebral aneurysms treated with the pipeline embolization device. Neurosurgery 2016;78:27-33.
5. Cohen JE, Gomori JM, Moscovici S, Leker RR, Itshayek E. Delayed complications after flow-diverter stenting: reactive in-stent stenosis and creeping stents. J Clin Neurosci 2014;21:1116-1122.
6. Mühl-Benninghaus R, Haußmann A, Simgen A, Tomori T, Reith W, Yilmaz U. Transient in-stent stenosis: a common finding after flow diverter implantation. J Neurointerv Surg 2019;11:196-199.
7. John S, Bain MD, Hui FK, Hussain MS, Masaryk TJ, Rasmussen PA, et al. Long-term follow-up of in-stent stenosis after pipeline flow diversion treatment of intracranial aneurysms. Neurosurgery 2016;78:862-867.
8. Wang T, Zhang CW, Richard SA, Chaohua W, Xie XD. Reactive in-stent stenosis of a pipeline embolization device in a child: a case report. Medicine (Baltimore) 2019;98:e18092.
9. Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001;19:369-386.
10. Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009;30:1964-1977.
12. Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, et al, CSPS.com Trial Investigators. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol 2019;18:539-548.
13. Stone GW, Brodie BR, Griffin JJ, Morice MC, Costantini C, St Goar FG, et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators. J Am Coll Cardiol 1998;31:23-30.
14. Tamhane U, Meier P, Chetcuti S, Chen KY, Rha SW, Grossman MP, et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. EuroIntervention 2009;5:384-393.
15. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, et al, Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005;112:2826-2832.
17. Takigawa T, Matsumaru Y, Hayakawa M, Nemoto S, Matsumura A. Cilostazol reduces restenosis after carotid artery stenting. J Vasc Surg 2010;51:51-56.
18. Galyfos G, Geropapas G, Sigala F, Aggeli K, Sianou A, Filis K. Meta-analysis of studies evaluating the effect of cilostazol on major outcomes after carotid stenting. J Endovasc Ther 2016;23:186-195.
19. Nakagawa I, Wada T, Park HS, Nishimura F, Yamada S, Nakagawa H, et al. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis. J Vasc Surg 2014;59:761-767.
20. Hassan AE, Zacharatos H, Grigoryan M, Tekle WG, Khan A, Siddiq F, et al. Open-label phase I clinical study to assess the safety and efficacy of cilostazol in patients undergoing internal carotid artery stent placement. Interv Neurol 2017;6:42-48.
21. Aguilar Pérez M, Bhogal P, Henkes E, Ganslandt O, Bäzner H, Henkes H. In-stent stenosis after p64 flow diverter treatment. Clin Neuroradiol 2018;28:563-568.
22. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 2004;44:1373-1385.
23. Monteiro A, Lopes DK, Aghaebrahim A, Hanel R. Optical coherence tomography for elucidation of flow-diversion phenomena: the concept of endothelized mural thrombus behind reversible in-stent stenosis in flow-diverters. [published online ahead of print Mar 22, 2021]Interv Neuroradiol 2021;
25. Zhang Z, Foster JK, Kolm P, Jurkovitz CT, Parker KM, Murrah NV, et al. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial. Am Heart J 2006;152:770-776.